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ABSTRACT 
Background: Diabetes mellitus is associated with an excessive 
cardiovascular morbidity and mortality. More recent data show that there 
may be a specific diabetic cardiomyopathy not associated to 
atherosclerotic coronaropathy. In fact, for reasons still not compltetaly 
understood, some diabetic subjects developed an earlier, more rapidly 
evolving, serious myocardiopathy with a worse prognosis than non-
diabetic subjects, in the absence of atherosclerotic vascular lesions. 
Objective: The aims of the study were , first, to obtain  an adequate 
model of the most dangerous complications of diabetes: 
Cardiomyopathy. Second, to study alteration of vascular response in 
diabetes. Third, to characterize SHHF/Mcc-fa/fa strain, as congenital 
model of diabetic cardiomyopathy. 
Methods: Initially, cardiac hypertrophy was obtained by placing a 
titanium clip (Ø 0.8 mm) around abdominal aorta proximal to renal 
arteries. The animals were studied 1 and 3 months after aortic 
coarctation. Cardiac contractility was evaluated through cannulation of 
the left ventricle (under anesthesia) to measure pressure and derived 
parameters. At the same time we investigated vascular reactivity in 
Wistar STZ rats after 11-and 18-weeks to induction of diabetes. The 
animals were randomized into four groups. Each group received 
cumulative escalating doses of: Endothelin-1, big-Endothelin-1, 
VI 
Angiotensin I and Angiotensin II, respectively, and blood pressure was 
recorded. 
Then, we prepared Wistar rats inducing cardiac hypertrophy with 
titanium clip method, and 1-month after aortic coarctation, the same rats 
were subjected to STZ 50 mg/kg i.v. administration. Unfortunately, we 
got a high rate mortality (> 80%). Thus we decided to change this model. 
It was recently available SHHF Mcc/fa-fa rats, recessive homozygotes 
for fa gene, and characterized by the expression of a Metabolic 
Syndrome (100%) associated to cardiomyopathy. So we decided to study 
the evolution of the Syndrome at different age, comparing this strain with 
WKY (age-matched rats), SHR (spontaneously hypertensive rats) and 
ZDF (Diabetic rats). We evaluated functional and humoral alterations 
and the nociceptive sensitivity to monitoring the evolution of neuropathy, 
another frequently diabetic complications. 
Results: The left ventricular mass (obtained from ratio of left ventricular 
mass to body weight) of rats subjected to aortic banding increased greatly 
in both 1- and 3-month groups with respect to sham-operated rats (p= 
0.008 and p= 0.014 respectively). On the contrary, hypertrophic rats did 
not show hemodynamic modifications with respect to sham-operated 
animals: left ventricular pressure, left ventricular end-diastolic pressure 
and heart rate seemed not to be modified by abdominal aortic coarctation 
in both groups (1- and 3-month coarcted rats). 
VII 
Body weight in 11- and 18-weeks diabetic rats was markedly reduced 
(p<0.0001) and glycemia was strongly increased (p<0.0001). 
The administering of Et-1 produced in both diabetic groups a typical 
significant biphasic effect : hypotension followed by hypertension 
significantly reduced both 11- and 18-weeks. 
SHHF-Mcc-fa/fa strain was characterized by high basal pressure level at 
6-months of age, hypercholesterolemia, hypertrigliceridemia, 
hyperinsulenemia in euglycemia conditions both 6-and10-months of age 
(p<0.0001). In addition, this strain had a reduction of nociceptive 
sensibility  increasing times reaction at 6-months of age and a 
progression nociceptive function impairment at 10-months of age. 
Conclusions: These results identify SHHF Mcc-fa/fa rat as a congenital 
model to better understand the physiopathology modifications  that lead 
to diabetic cardiomiopathy. 
 
 - 1 - 
1. INTRODUCTION 
 
The conventional wisdom holds that diabetes causes myocardial 
contractile dysfunction through accelerated atherosclerosis and 
hypertension. Much less appreciated and more controversial is the notion 
that diabetes mellitus affects cardiac structure and function, independent 
of blood pressure or coronary artery disease1-3. The term Diabetic 
Cardiomyopathy (DCM) was first proposed by Rubler et al. in 1972, after 
clinical encounter of a specific type of cardiomyopathy that is closely 
associated with diabetes. An increasing body of evidence has 
independently confirmed the existence of such cardiac complications of 
diabetes4. DCM is characterized by a cascade of myocardial changes that 
occurs in diabetes mellitus with interstitial fibrosis, myocardial  
hypertrophy and microcirculatory abnormalities. These cardiovascular 
complications compromise cardiac performance ultimately resulting in 
cardiac failure5. The epidemiological link between diabetes mellitus and 
the development of heart failure, independent of atherosclerotic 
cardiovascular disease, has been evident for the better part of three 
decades. Several theories have been proposed, including Protein Kinase 
C (PKC) activation, enhanced oxidative stress, and accumulation of 
advanced glycation end products (AGEs). Among these, PKC activation 
no doubt plays a significant role4. The increased risk of heart failure 
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persists in the diabetic patients after considering age, blood pressure, 
weight, cholesterol, as well as history of coronary artery disease. 
Notably, there is a significant association between diabetes and diastolic 
dysfunction leading to congestive heart failure in the absence of impaired 
systolic function. The association between diabetes and cardiomyopathy 
is strongest among individuals with microvascular complications of 
diabetes that parallels the duration and the severity of hyperglycemia. 
However, it has been difficult to ascertain from these epidemiological 
correlations the causal relationship between the commonly observed 
metabolic abnormalities and the specific cardiac phenotype6-9.  
 
1.1 Pathogenesis of Diabetic Cardiomyopathy:  
Cardiomyopathy is a complicated disorder, and several factors have been 
associated with its development. These include increased stiffness of the 
left ventricular wall associated with accumulation of connective tissue 
and insoluble collagen, depressed autonomic function, impaired 
endothelium function and sensitivity to various ligands (e.g. β-agonists), 
and abnormalities of various proteins that regulate ion flux, specifically 
intracellular calcium. More recently, there is a generalized view that 
diabetic cardiomyopathy also occurs as a consequence of altered fuel 
metabolism10. The 3 characteristic metabolic disturbances evident in 
diabetic states are hyperlipidemia (usually in the form of increased 
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triglycerides and nonesterified fatty acids [NEFAs]) and  early 
hyperinsulenemia followed by pancreatic β-cell failure, leading 
eventually to hyperglycemia. Type 1 diabetes differs principally from 
type 2 diabetes in that it is unaccompanied by a period of 
hyperinsulenemia and is characterized by early- as opposed to late-onset 
hyperglycemia. Alterations in body mass (obesity) and adipocytokines 
(leptin, adiponectin) have also been implicated in the cardiovascular 
pathophysiology observed in diabetes. As such, the effects of increased 
NEFAs, altered insulin action, and hyperglycemia can be considered 
triggers to the cardiac phenotype in diabetes. An understanding of the 
cellular effects of these metabolic disturbances on cardiomyocytes should 
be useful in predicting the structural and functional cardiac 
consequences. Extensive cellular and molecular studies have identified 
putative mediators, effectors, and targets of these metabolic triggers in 
the pathogenesis of cardiac dysfunction in diabetes11 (Fig. 1). 
 
 
 - 4 - 
 
 
Figure 1. The relationship between diabetic metabolic disturbances 
(triggers) and the mediators, effectors, and intracellular targets that lead 
to a diabetic cardiomyopathic phenotype. 
 
1.1.1 Increased NEFAs 
NEFAs play a critical role in triggering the development of cellular insulin 
resistance, but also have been implicated in the development of myocardial 
contractile dysfunction. NEFAs play a central role in altering cellular 
insulin signalling through several mechanism leading to insulin resistance 
and compensatory hyperinsulenemia. In turn, hyperinsulenemia is an 
important trigger to the development of cardiac hypertrophy in diabetic 
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cardiomyopathy. NEFAs  induce the activation of atypical protein kinase C 
(PKC) θ, a serine/threonine Kinase that phosphorylates and subsequently 
activates IkB kinase.  IkB kinase  phosphorylates  serine residues on 
insulin receptor substrate-1 (IRS-1), inhibiting its ability to bind SH2 
domains of the p85 regulatory subunit of phosphatidylinositol 3-kinase 
(PI3K), impairing insulin signal transduction. Although this mechanism is 
active in skeletal muscle and adipose tissue, it has been less clear whether 
similar mechanisms are apparent in cardiac muscle. Increases  in 
intracellular NEFAs can also alter insulin signalling without affecting IRS-
1/PI3K activation (figure 2). 
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Figure 2. Role of increased NEFAs in the pathogenesis of cellular 
insulin resistance. There are several putative mechanisms including the 
induction of atypical PKC, phosphorylation, and activation of I B kinase 
which serine phosphorylates and deactivates IRS-1. NEFAs may also 
activate the phosphatase PTEN, decreasing the tris-inositol phosphates to 
which the pleckstrin domain of Akt-1 binds. Finally, NEFAs can 
contribute to ceramide production, triggering cellular apoptosis. 
 
Akt-1 activation  is critically dependent on the generation of 
phosphatidylinositol 3,4,5-trifosphate (PtdIns(3,4,5)P3) to bind the N-
terminal pleckstrin domain and activate membrane bound kinase 
responsible for the phosphorylation of serine and threonine residues on 
Akt-1 that confer catalytic and regulatory properties. NEFAs  are natural 
ligands for the nuclear receptor, peroxisome proliferator-activated 
receptor (PPAR) γ, and can induce the upregulation of the phophatase 
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and tesin homolog deleted on chromosome 10 (PTEN) which 
dephosphorylates PtdIns(3,4,5)P3, preventing the activation of Akt1. 
NEFAs can directly alter myocardial contractility independent of altered 
insulin action by increasing NEFA flux into the myocardium. Recent 
evidences suggest that increases in fatty acyl coenzyme A (CoA) esters 
within cardiac myocites may modulate the contractile state of the 
myocardium by opening of the KATP channel. Activation of the KATP 
channel leads to shortening of the action potential and reduces 
transarcolemmal calcium flux and subsequently myocardium 
contractility. Finally, the increased intracellular accumulation of NEFAs 
may directly contribute to cell death under circumstances in which 
accumulating intracellular NEFAs do not undergo β-oxidation. The 
reaction between palmityol-CoA, an intracellular intermediate of NEFAs, 
and serine leads to the generation of the sphingolipid ceramid, and this 
reaction may be facilitated by the cytokine, tumor necrosis factor TNFα. 
Ceramide can induce cellular apoptosis through the induction of nuclear 
factor kB, caspase 3 activation, cytochrome c release, and can inhibit 
DNA repair by blocking poly ADP ribose polymerase. Under these 
circumstance, increased NEFAs seems to cause lipotoxicity. Although 
lipotoxicity has been implicated in the reduction in pancreatic β-cell 
reserves, the relevance of these findings in the myocardium remain 
controversial. Thus, NEFAs play a central role not only in inducing 
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cellular insulin resistance, but also indirectly affecting myocardial 
contractility and, under specific circumstances, in the promotion of 
cardiomyocyte cell death12-22. 
 
1.1.2 Hyperinsulinemia 
Insulin resistance occurs as part of a cluster of cardiovascular-metabolic 
abnormalities commonly referred to as the "insulin resistance syndrome" 
or the "metabolic syndrome". Currently, insulin resistance is defined 
clinically as the inability of a known quantity of exogenous or 
endogenous insulin to increase glucose uptake and utilization in an 
individual as much as it does in a normal population. As stated 
previously, insulin action is the consequence of the binding of insulin to 
its plasma membrane receptor and the transmission of its signal 
throughout the cell by a series of protein-protein interactions and 
signalling cascades4. Cellular insulin resistance may precede frank 
diabetes by a decade or more and requires compensatory increases in 
plasma insulin levels to maintain glucose homeostasis in the face of 
impaired cellular insulin action, principally in skeletal muscle and liver. 
The nature and extent of the cellular insulin resistance may be selective 
to certain organ systems and may vary in terms of the metabolic, 
mitogenic, prosurvival, and vascular actions of insulin. Systemic 
hyperinsulenemia may accentuate cellular insulin action in insulin 
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responsive tissues, such as the myocardium, that do not manifest cellular 
insulin resistence. In this regard, the mitogenic actions of insulin on 
myocardium during chronic systemic hyperinsulinemia bear directly the 
commonly observed finding of cardiac hypertrophy in diabetic 
cardiomyopathy. There are at least 3 cellular mechanisms whereby 
hyperinsulenemia mediates cardiomyocytes hypertrophy (figure 3). 
 
 
 
Figure 3. Alternative pathways whereby compensatory hyperinsulinemia 
contributes to myocyte hypertrophy through the sympathetic nervous 
system activation and MAP kinase/ERK pathways at a time when insulin 
receptor mediated Akt-1 activation is impaired. 
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Acutely, insulin stimulates growth through the same PI3Kα/Akt-1 
pathway by which it mediates glucose uptake. Akt-1  phophorilatesand 
inactivates glycogen synthases kinase-3β (GSK-3β), a well –recognized 
inhibitor of nuclear transcription governing the hypertrofic processvia the 
nuclear factor in activated lymphocytes (NFAT-3). In addition, Akt-1   
activates the mammalian target of rampamycin (mTOR) that activates the 
p70 ribosomal subunit S6kinase, leading to increased actions mediated 
through the insulin receptor may be mitigated when insulin signalling 
through the PI3Kα/Akt-1 pathway is impaired during chronic 
hyperinsulenemia. However, chronic hyperinsulenemia may augment 
myocardial Akt-1 activation indirectly  through increased sympathetic 
nervous system activation. Recent evidence suggests that chronic Akt-1 
activation in cardiac myocites is mediated through β2-adrenergic 
receptors via protein chinase A and Ca2+-calmodulin dependent kinase 
(CaMK) and these mechanisms may predominate when insulin signalling 
is attenuated through the PI3Kα pathway. 
In addiction, there are other insulin-mediated, but Akt-1-indipendent, 
pathways that  may be operative, most notably the extracellular signal-
regulated kinase (ERK)/mitogen-activated protein (MAP) kinase 
pathways. Significant cellular evidence exists for an insulin-induced 
activation of the p38 MAP kinase pathway, as well as prenylation of both 
Rho and Ras in the setting of hyperinsulenemia, leadind to myocyte 
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hypertrophy and expansion of the extracellular matrix (figure 3). These 
redundant pathways provide a strong mechanistic basis for the 
development of cardiac hypertrophy associated with chronic 
hyperinsulenemia as an early accompaniment of type 2 diabetes, even 
though the glucoregulatory effects of insulin are attenuated23-26. 
 
1.1.3 Hyperglycemia 
Hyperglicemia plays a pivotal role in the development of both 
microvascular and macrovascular complications. The results of the 
Diabetes Complications and Control Trial (DCCT) indicate that 
hyperglycemia is a major contributor to microvascular disease (i.e. 
retinopathy and nefropathy) in type 1 diabetes.  In addition, results from 
DCCT together with those of other smaller studies, suggest that intensive 
glycemic control can reduce cardiovascular disease. On the other hand, 
the actual effect of hyperglycemia on the development and progression of 
macrovascular complications remains unclear and even somewhat 
controversial, particularly in type 2 diabetes. The complicated nature of 
the metabolic abnormalities in type 2 diabetes and the relative roles of 
these associated conditions in the development of  macrovascular disease 
make definite conclusions somewhat difficult. Nevertheless, certain 
aspects of postprandial glucose levels, are associated with macrovascular 
disease, and there are a number of basic mechanisms to explain these 
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associations that could lead to the development of cardiovascular disease. 
These abnormalities include activation of the sorbitol pathway, oxidative 
stress, and generation of reactive AGEs and AGE precursors. Results of 
these events include endothelial dysfunction, altered properties of key 
proteins (for example, due to glycation of structural proteins), and 
generation of proinflammatory cytokines. These considerations suggest 
that hyperglycemia plays an important, but as yet not clearly defined, role 
in clinical macrovascular disease4. 
The mechanism whereby hyperglycemia mediates tissue injury through 
the generation of reactive oxygen species has been elucidated largely 
through the work of the Brownlee and colleagues. Hyperglycemia leads 
to increase glucose oxidation and mithocondrial generation of 
superoxide. In turn, excess superoxide leads to DNA damage and 
activation of poly (ADP ribose) polymerase (PARP) as a reparative 
enzyme. PARP, through inhibition of glyceraldehyde phosphate 
dehydrogenase (GAPDH), diverts glucose from glycolytic pathways into 
alternative fates, including AGE formation, hexosamine and polyol 
pathway flux, protein kinase C activation, which are believed to mediate 
hyperglicemia-induced cardiac tissue damage.  In this regard, increased 
formation of AGE forms irreversible cross-links with many 
macromolecules such as collagen, leading to tissue fibrosis, inactivation 
of SERCA2, and ryanodine receptor calcium-release channel, impa
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cardiac relaxation, contractility, and ventricular stiffness.  Increased 
hexosamine influx reduces SERCA2a protein levels, resulting in 
prolonged calcium transients, QT duration increase and conseguetly,   
delayed myocardial relaxation. Increased hexosamine influx also impairs 
insulin signal transduction and contributes to insulin resistance. Increased 
polyol flux is associated with a decrease in intracellular glutathione and 
augmentation in cell apoptosis. Conversely, inhibition of polyol flux 
protects hearts from ischemic injury. Finally, activation of PKC-β2 leads 
to left ventricular hypertrophy, cardiac myocite necrosis, multifocal 
fibrosis, and decreased left ventricular performance, resulting in 
cardiomyopathy. Taken together, hyperglycemia, through multiple 
pathways, causes cardiac cellular and functional changes, possibly 
contributing to the development of cardiomyopathy10. 
 
1.1.4 Diabetic cardiomyopathy: Unifying hypothesis 
Epidemiological, clinical and experimental evidence suggest the 
existence of a different form of cardiomyopathy related to pathogenic 
cellular and molecular changes that accompany diabetes mellitus. Figure 
4 is a schematic illustration of a unifying hypothesis that links NEFAs, 
hyperinsulenemia, and hyperglicemia to the structural and functional 
phenotypes in cardiac cardiomyopathy. The magnitude of ventricular 
hypertrophy may depend on the magnitude and duration of 
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hyperinsulenemia that, in turn, may depend on magnitude and 
distribution of increasing NEFAs. In contrast, the extent of systolic 
dysfunction may depend more on the magnitude and duration of 
hyperglicemia and presence or absence of insulin. Diastolic abnormalities 
may occur as a consequence of either hypertrophy or hyperglycemia. As 
such, hypertrophy and diastolic abnormalities are observed most 
commonly and earlier than systolic abnormalities and thus dominate the 
clinical findings. The paradigm reconciles the distinctive cardiovascular 
feature attributable to type 1 (hypoinsulinemic/hyperglicemia→systolic 
dysfunction) and type 2 (hyperinsulemic/hyperglicemic→hypertrophy 
and diastolic dysfunction) diabetes in experimental models studied in 
vivo. In humans  with type 1 diabetes, systolic dysfunction is less evident 
than in STZ-induced models because these patients receive exogenous 
insulin, making them metabolically similar to a type 2 diabetic from this 
mechanistic perspective. These findings are generally consistent with the 
established cellular consequence of increased NEFAs, hyperinsulenemia 
and hyperglycemia on cardiac structure and function. These insights 
afford  the opportunity to design therapeutic approaches targeted at 
specific pathogenic mechanisms including suppression of lipolysis, 
maturation of adipocytes, and restoration of cellular insulin action, in 
addition to the traditional target of maintaining euglycemia11. 
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Figure 4. Schematic illustration of a unifying hypothesis that links 
NEFAs, hyperinsulinemia, and hyperglycemia to the structural and 
functional phenotypes in diabetic cardiomyopathy. 
 
1.1.5 Prevention and Treatment 
Treatment of congestive heart failure in the diabetic patient should follow 
the same guidelines as nondiabetic patients, with a few notable 
exceptions. Treatment of hypertension and hypercholesterolemia along 
with avoidance of excessive alcohol intake and cessation of smoking are 
advised for all patients. Diabetic patients requiring thiazide diuretics or 
β-blocking agents may run the risk of impaired insulin secretin or, 
conversely, profound or marked hypoglicemic reactions. The former 
 - 16 - 
problem may be improved by the use of cardioselective  β-blockers with 
intrinsic sympathomimetic activity. Similarly, arterial reflexes may be 
impaired in diabetic persons with autonomic dysfunction. Thus preload- 
and afterload-reducing agents should be used cautiously in diabetic 
patients. Although an altered myocardial sensitivity to glycoside has not 
been established clinically, isolated muscle from diabetic rats has shown 
a greater tendency to contracture when exposed to ouabain. 
Finally, the role of intensive hypoglycemic therapy in the primary 
prevention or several of myocardial dysfunction remains to be elucidated. 
The results of clinical and experimental studies are equivocal, though 
encouraging results of metabolic control in improving myocardial 
function are presented. These studies suffer from inadequate sample size, 
varying patient populations, and variable institutions and duration of 
treatment. We agree that maintenance of metabolic control of diabetics is 
crucial, but we cannot support intensive insulin treatment with its 
attendant increased risk of hypoglycaemic and ketoacidosis in patients 
with myocardial dysfunction until the benefit-to-risk ratio for such 
treatment is better known27. 
 
1.2 Diabetic Neuropathy 
Diabetic neuropathy is common in diabetic patient, with prevalence of 
more than 50%. The pathogenesis is multifactorial and is considered to 
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be rooted in both hyperglicemia-induced pathologic changes intrinsic to 
neurons and ischemia-induced neuronal damage resulting from decreased 
neurovascular blood flow. Because of the vascular elements, diabetic 
neuropathy is also considered to be a form of microvascular  
complications. Diabetes induces pathologic changes in the neurotrophic 
microvessels reduces blood flow via reduction in endothelial- and nitric 
oxide-dependent vasodilatation, and alters the expression and action of 
vasoconstrictors endotelina-1 (Et-1) and vascular endothelial growth 
factor (VEGF). This point of view is supported by studies in diabetic 
animal models. In vivo expression of VEGF restored blood flow in 
neurotrophic blood vessels as well as nerve functions in streptozotocin-
induced diabetes. PKC activation has been known to cause similar 
changes in microvessels. Suppression of PKC activity streptozotocin-
diabetic rats rectified diabetes-induced impairments in nerve blood flow, 
conduction velocity, the sodium-potassium pump (Na+, K+-ATPase), and 
glutathione deficits. Furthermore, inhibition of PKC-β II activity with the 
use of a selective inhibitors restored motor nerve conduction velocity and 
endoneuronal blood flow that were impaired by diabetes. All of this 
evidence supports a role of PKC, especially the PKC-βII isoform, in the 
pathogenesis of diabetic neuropathy11. 
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1.3 Animal models for diabetic cardiomyopathy 
The altered cardiac phenotypes associated with diabetic cardiomyopathy 
have been investigated in a wide array of experimental models. From a 
mechanicist perspective, the manifestations of diabetic cardiomyopathy 
should be predictable based on the duration and the severity of the 
abnormalities in NEFAs, insulin, and glucose homeostasis.  
Models of Hyperglicemia without hyperinsulenemia  
Streptozotocin (STZ) and alloxan are the 2 of the most common islet  cell 
toxins that are used to induce type I diabetes in experimental animal 
models. The metabolic features include the prompt development of 
profound hyperglicemia (25 to 30 mmol/L), modest hypertriglyceridemia 
(200 to 400 µmol/L), ketosis, and markedly reduced plasma insulin levels 
(<20 pmol/L). As such, the model is particularly useful in examining the 
effects of hyperglycemia in the absence hyperinsulinemia. 
STZ- and alloxan-induced diabetes have been associated with myocardial 
atrophy rather than hypertrophy. This is associated with loss of 
contractile proteins, myocyte dropout without reparative fibrosis, 
consistent with the absence of the mitogenic and prosurvival effects of 
insulin. Decreases in cardiac mass have also been noted with cardiac 
specific knockout of the insulin receptor associated with ventricular 
dilatation and impaired left ventricular (LV) systolic performance. There 
has been consistent evidence of intramyocardial lipid accumulation 
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reflecting a compensatory shift in myocardial preference for fatty acids in 
the absence of insulin mediated glucose uptake. Alterations in SERCA2 
have been reported in association with the hyperglycemia in STZ induced 
diabetes leading to decreased SR calcium sequestration and intracellular 
calcium overload. Decreases in contractile proteins, such as α-actin and 
myosin ATPase activity, have been noted in association with shift in 
myosin heavy chain isoforms from α to β, contributing to decreased 
systolic tension development28-31. The functional consequences of these 
cellular effects have been studied in vivo or vitro measurements. For 
example, systolic and diastolic dysfunction have been detected by using 
echocardiography in STZ diabetic animals. With the use of in vivo 
catheterization of these animals, elevated left ventricular end-diastolic 
pressure and reduced left ventricular systolic pressure with diminished 
the maximal rate of rise (+dP/dt) or the maximal rate of decrease (-dP/dt) 
were observed. Reduced peak left ventricular pressure and ±dP/dt were 
confirmed in ex vivo perfused STZ hearts10. These studies suggest that 
experimental type 1 diabetes, characterized principally by hyperglicemia 
is associated with altered calcium handling, impaired diastolic function, 
altered contractile proteins, and progressive systolic dysfunction as 
magnitude and duration of the hyperglicemia progresses. These 
abnormalities occur in the absence of myocyte hypertrophy or fibrosis. 
The findings are consistent with a dominant influence of hyperglycemia 
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and the absence of the influence of insulin. Thus, hyperglicemia alone is 
sufficient to account for the functional, but not necessarily the structural, 
changes observed in diabetic cardiomyopathy. 
Models of Hyperinsulenemia with or without hyperglicemia  
Recently, evidence of cardiomyopathy has also been reported in animal 
models of insulin resistance and type 2 diabetes (ZDF rats and ob/ob or 
db/db mice)3. Models of type 2 diabetes are metabolically distinct from 
type 1 diabetes largely related to increased plasma insulin levels 
associated with altered cellular insulin action. Increased NEFAs and 
marked hyperinsulenemia are early accompaniments, whereas 
hyperglicemia is a later development attributable to exhaustion of 
pancreatic β-cell reserves. However, the cardiac manifestations in 
experimental models of type 2 diabetes vary considerably based on the 
onset and severity of these metabolic perturbations, as well as the 
complex interactions of intramyocardial lipids, insulin, and glucose on 
the cardiomyocyte structure and function.  
Many of the commonly used experimental models of type 2 diabetes are 
associated with obesity caused by genetic perturbations in the Ob gene 
and its product, leptin. Leptin is a 16-kDa peptide produced by 
adipocytes  that acts via specific receptors on the hypothalamus to inhibit 
food intake and increase energy expenditure. Notably, leptin receptors 
have been identified in the rat myocardium and regulate fatty acid 
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oxidation independent of effects on the acetyl CoA-malonyl CoA axis. 
Leptin has also been shown to stimulate myocyte hyperplasia in rats and 
humans through both PI3-K- and ERK1/2-dependent mechanisms, 
similar to insulin. The metabolic phenotype associated with both leptin-
deficient (ob-/ob-) and leptin receptor-deficient (db-/db-) mice include 
obesity, insulin resistance, compensatory hyperinsulenemia, 
hypertriglyceridemia, and various degrees of hyperglycemia. The cardiac 
phenotype of the ob-/ob- (leptin-deficient) mice has been studied both 
early and later in its development with varying results. LV hypertrophy 
and intramyocardial lipid accumulation are evidence both early and late, 
suggesting that hyperleptinemia is not necessary for the development of 
LV hypertrophy. 
The hyperleptinemic db-/db- (leptin receptor-deficient) mice have a 
similar metabolic phenotype, but more profound hyperglicemia (30 to 50 
mmol/L) manifest earlier in development31-33. In db/db mice, systolic and 
diastolic dysfunction were detected by echocardiography. With the use of 
ex vivo perfused hearts from db/db mice, augmented left ventricular end-
diastolic pressure and reduced cardiac output and cardiac power have 
also been observed. Given that rodents are resistant to atherosclerosis, 
these models provided strong evidence for the occurrence of diabetic 
cardiomyopathy10.  
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A similar evolution in cardiac phenotype is evident in genetically 
engineered rat models involving the absence of a functional  leptin 
receptor. The Zucker fatty (ZF) rat is characterized metabolically by 
hyperleptinemia and consequent obesity, hyperlipidemia, and marked 
hyperinsulenemia with the late onset of hyperglicemia. As such, the 
model is characteristic of obesity and insulin resistance early (3 to 6 
months). In contrast, the Zucker diabetic fatty (ZDF) rat has a similar 
genetic background but demonstrates earlier hyperglicemia, consistent 
with metabolic feature of type 2 diabetes. 
The morphological features of the ZF rat include increased 
intramyocardial lipid and increased myocardial mass. Hypertrophy is 
evident in individual myocytes and whole hearts where there is an 
associated expansion in the extracellular matrix. However, cardiac 
functional abnormalities have been observed  inconsistently in isolated 
heart preparations with decreased cardiac power and systolic wall stress 
in some studies, whereas LV pressures and LV dP/dt and the rate-
pressure product are maintained in others. In contrast to the ZF rats, the 
ZDF rats do not demonstrate consistent increase in cardiac mass. At 2 
months, there is increased mass in the presence of marked 
hyperinsulenemia at a time when glucose levels are normal. However, by 
3 months, there is no increase in mass when plasma glucose levels are 
high (27 mmol/L) and plasma insulin levels are reduced. Fredersdorf et al 
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estabilished the importance of the balance between hyperglycemia and 
hyperinsulenemia in 5-months old ZDF rats by controlling 
hyperglycemia with exogenous insulin and demonstrating increased 
cardiac mass, whereas ZDF rats that remained persistent hyperglycaemic 
had no increase in mass. Thus, hyperinsulinemic ZF rats have myocardial 
hypertrophy and variable degrees of diastolic abnormalities, whereas the 
diabetic ZDF rats have smaller increase in cardiac mass and impairments 
in LV systolic function in isolated hearts but not intact models. These 
findings are consistent with the cellular effects of hyperinsulenemia to 
induce cardiac hypertrophy in contrast to the effects of hyperglycemia that 
mitigate hypertrophy and affect systolic dysfunction to a greater extent34-36. 
SHHF Mcc-fa/fa is a genetic model  of hypertension and end-stage 
congestive heart failure (10-14 months). SHHF rats that are homozygous 
for the corpulent (facp) gene are leptin resistant due to failure to produce a 
functional leptin receptor. Consequently, they become markedly obese, 
secondary to leptin resistance. Obese SHHF rats exhibit anomalies 
similar to human Metabolic Syndrome, such as hyperinsulenemia, 
impaired glucose tolerance, hyperlipidemia, hypertension and cardiac 
hypertrophy. In addition, this rat model of leptin resistance and obesity 
shows alterations in neurohumoral activation that may modulate blood 
pressure control and progression to congestive heart failure37. SHHF 
Mcc-fa/fa rat represents a congenital model of diabetic cardiomyopathy, 
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which exhibits several hallmark signs of the human disease state38. 
However, this strain have not yet been extensively investigated in the 
evolution of their pathology.  
Models of increased intramiocardial lipid without Hyperinsulenemia or 
hyperglycemia 
Mice with cardiac specific overespression of PPARα  is a model 
characterized by cardiac dysfunction that is mediate by increased NEFA 
uptake and intracellular accumulation. The model does not possess 
characteristic features of diabetes. However, this model is particularly 
useful in studying the contribution of excess intracellular lipid 
accumulation to cardiac contractile dysfunction, in the absence of 
hyperglycemia and hyperinsulenemia. Recent data using transgenic  
murine models of cardiac specific overespression of fatty acid transport 
protein (FATP) demonstrated a cardiac phenotype that feature diastolic 
dysfunction. Taken together, it is abundantly clear that increased 
circulating NEFAs, a ubiquitous feature of both type 1 e 2 diabetes, 
contribute fundamentally not only to the development of both insulin 
resistance and compensatory hyperinsulenemia but also can directly 
affect cardiac function. 
Cardiovascular manifestations  in humans with type 1 and 2 diabetes 
In clinical studies of asymptomatic diabetics has been observed cardiac 
abnormalities such as LV hypertrophy and impairment in both 
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isovolumic relaxation and ventricular filling, particularly among diabetic 
women. In fact, estrogens induced activation of Akt-1 and its 
transcriptional effects in cardiomyocytes. In addition, clinical studies 
have demonstrated consistent abnormalities in coronary flow reserve in 
patients with diabetes in the absence of epicardial heart disease. Both 
findings correlate closely with macrovascular complications, particularly 
autonomic dysfunction. What is surprising that the clinical manifestation 
are similar in both type 1 and type 2 diabetics36-43. These clinical findings 
are different  than animal models. Taken together, experimental data 
obtained using animals models of diabetes should be used with caution 
when extrapolating to the human condition10. Type 1 diabetic patients 
are treated with insulin and are therefore not truly hypoinsulemic as in 
the STZ models. Insulin has been shown to mitigate systolic dysfunction 
in STZ-induced diabetes in rats. Notably, systolic dysfunction at rest and 
during exercise in type 1 diabetes is observed most commonly in patients 
with microvascular complications, a reflection of poor glycemic 
control44-45. 
 
1.4 Aim of the study 
The aims of the present study were, first, to obtain an adequate model to 
investigate physiopatological modifications that lead to one of the most 
dangerous  complications of diabetes, cardiomyopathy. Second, to study 
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alteration of  vascular response  in diabetes. Third, we to characterize 
SHHF/Mcc-fa/fa rat, as a congenital model of diabetic cardiomyopathy, 
by exploring the pathological evolution of Metabolic Syndrome and 
cardiac complications, especially regarding functional and humoral 
alterations. 
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2. METHODS 
2.1 Animals  
Rats were housed in makrolon cages (Tecniplast Gazzada) with food 
(pellets, Mucedola, except for the ZDF/Gmi-fa/fa rats which were given 
a Purina 5008 diet, Charles River) and water ad libitum. The light cycle 
was automatically controlled (on at 7:00 AM and off at 7:00 PM), and 
the room temperature was thermostatically controlled to 22 ± 2 °C, 
relative humidity: 50 ± 15%. Before the experiment, the animals were 
housed in these conditions at least for 7 days to become acclimatized. 
Studies were performed in accordance with Italian and European 
regulations on protection of  laboratory animals. 
 
2.2 Hypertrophic myocardiopathy: induction and characterization 
2.2.1 Cardiac hypertrophy induction 
Thirty six male Wistar rats (Harlan Italy S.p.A., Via Fermi 8, Correzzana 
(Mi), Italy) weighting 150-175 g were used.  
Rats were numbered, randomized and assigned to sham or hypertrophied 
group. Each group was initially formed by ten animals. The animals were 
anesthetized (60 mg/2 mL/kg ip Pentobarbital) and positioned on their 
right side. Abdominal aorta was exposed through an ipsilateral incision 
and ventricular pressure overload hypertrophy was elicited by 
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constriction of a titanium clip (Ǿ 0.8 mm) around the vessel. Sham-
operated rats underwent the same surgical procedure but without 
insertion of the clip. The cutaneous incision was sutured and animals 
kept alone in cages for the first 48 h. The animals that died within the 
first 48h were substituted. The study was divided into phases: the first 
provided for one-month survival of the rats after coarctation, the second, 
three month. 
 
2.2.2 Evaluation of cardiac contractility of hypertrophic rats 
Cardiac contractility was evaluated through cannulation of the left 
ventricle to measure pressure and derived parameters. Such procedure 
was performed  utilizing a polyethylene catheter (PE50) connected to a 
pressure transducer (p23Db; Statham Wood Dale, Il. U.S.A.) attached to 
a preamplifier. The animals were stabilized for 15-20 minutes, after 
which basal values were recorded for at least five minutes. The 
monitored parameters included: left ventricular pressure (LVP) and its 
maximal rate of rise (LVdP/dt) and decrease (-LVdP/dt) and heart rate 
(HR), all recorded and analyzed via a computerized data acquisition 
system (IOX vers. 1.7.0, EMKA). At the end of homodynamic studies 
the animals were euthanized by a lethal dose of Nembutal the abdomen 
opened and the clip position checked. Then heart, lungs and liver were 
dried and carefully weighed. 
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2.3 Vascular reactivity in Streptozotocin-induced diabetic rats 
2.3.1 Diabetes induction and animal preparation 
Male Wistar rats (Charles River – Calco CO Italy), weighting  280-320 g, 
were injected with STZ (50 mg/kg, iv; diabetic group) or vehicle sodium 
citrate buffer pH 4.5 (control group, “age-matched”) after an overnight 
fast. After 10 days, rats with blood glucose values > 400 mg/100 mL 
(Reflomat S, Boehringer) were including in this study. 
Rats were anesthetized by Pentobarbital sodium (Nembutal, 50 mg/kg 
ip), 11 and 18 weeks after induction of diabetes. Trachea was 
catheterized to improve breathing, right jugular vein for agonist injection, 
the left femoral vein for ganglion-blocking agent infusion and the left 
carotid artery to monitoring blood pressure by a pressure transducer 
(p23Db; Statham Wood Dale, Il. U.S.A.) connected to a preamplifier. 
 
2.3.2 Experimental protocol 
The animals were stabilized for 15 minutes and after we administered  a 
bolus of phenylephrine (Phe, 3 µg/kg iv)  and after 15 minutes bolus of 
acetylcholine (Ach, 3 µg/kg iv). After recovery, we administered 
cumulative  escalating doses of: 
a) Endothelin-1 (Et-1, 0.1 - 2 nmol/kg) 
b) Big Endothelin-1 (rbig-Et-1, 0.1 -  10 nmol/kg) 
c) Angiotensin II (Ang II, 0.001 - 10 nmol/kg) 
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d) Angiotensin I (Ang I, 0.001 -  10 nmol/kg) 
Each animal received only administration of escalating doses of one 
peptide. Blood pressure was recorded continuously along the 
experiments. 
 
2.3.3 Model of hypertrophic cardiomyopathy and diabetes 
Wistar rats were prepared, as describe in paragraph 2.2, to induce cardiac 
hypertrophy and 1-month after aortic coarctation were administered to 
the same rats, STZ 50 mg/kg i.v. Unfortunately, the 20 treated rats 
presented high rate mortality (> 80%). Thus we decided to abandon this 
model. 
 
2.4 Genetic Diabetic Cardiomyopathy model: Functional  and 
humoral evaluation 
It was recently commercially available SHHF Mcc/fa-fa rat strain. The 
homozygote rats for recessive fa gene of this strain, was characterized by 
the expression of Metabolic Syndrome 100% associated to 
cardiomyopathy. SHHF rats originated from a mating between the 
Koletsky rat (an Sprague Dawley derivate) and inbred SHR from the 
Okamoto strain. This colony exhibits the following traits: hypertension 
(100 percent), obesity (25 percent; expressed as an autosomal recessive 
cp/cp trait) and congestive heart failure (100 percent)46-47. So we decided 
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to evaluate the evolution of Syndrome at different age to characterize the 
model48-50. The study was conducted in comparison with normal, diabetic 
and hypertensive rat strains. The animals used were 30 male of each 
strain (Charles River – Calco CO Italy), 10 weeks old on arrival: “age-
matched” Wistar Kyoto (WKY), used as normotensive and euglycemic 
control, spontaneously hypertensive (SHR), Zucker diabetic fatty 
(ZDF/Gmi-fa/fa) and homozygote obese, spontaneously hypertensive 
heart failure-prone (SHHF Mcc-fa/fa) rats. All rats of each strain were 
enlisted at age of 6-10 months and randomly assigned to two age groups, 
based on arrival group.  
 
2.4.1 Nociception 
The exploitation of SHHF rats in comparison with WKY, SHR  and ZDF 
started with the assessment of their nociceptive sensibility by means of a 
“Tail-Flick” test.  
 
 
 
 
 
 
 
 Figure 5. "Tail Flick" apparatus 
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The rats of each strain and same age were put into a small cage with 
opening for the tail at rear wall. The tail was held gently by the 
investigator. Through the opening of a shutter, a light beam exerting 
radiant heat was direct to the distal third of the tail (Figure 5). We  have 
been observed the reaction of the animal for about 6 seconds. The rat 
tried to pull its tail away. The shutter has been switched closed as quickly 
as possible and the reaction time marked by instruments. The test has 
been repeated in triplicate and the values averaged. 
 
2.4.2 Humoral analysis 
Blood was sampled from tail vein of animals fasted for 6 hours at target 
ages two days after “Tail-Flick” test to measure plasma levels of glucose, 
triglyceride, cholesterol and insulin. 
 
2.4.3 Measurements of blood pressure, skin blood perfusion flow and 
aortic blood flow 
The hemodinamic was evaluated in anesthetized animals (1-2% 
Isofluorane in N2O/O2 mixture) fasted for 18 hours. Procedures: the right 
jugular vein was catheterized for ganglion-blocking agent infusion 
(Pentolinium, 0.075 mg/kg), the left jugular vein to peptide injection and 
the right carotid artery for blood pressure monitoring by a pressure 
transducer (p23Db; Statham Wood Dale, Il. U.S.A.) connected to a 
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preamplifier. Than, to monitor skin blood perfusion flow (PF), a laser 
Doppler probe was positioned on posterior left leg and data continuously 
recorded by a computerized acquisition system (Periflux 5000, Perimed, 
Italy). Blood flow microprobes, of a adequate internal diameter (1-1.5 
mm), was placed around the upper abdominal aorta just below the 
diaphragm and connected to a pulsed Doppler flow meter (mod CB 9000, 
Crystal Biotech, USA). After instrumentation, the animals were placed in 
an incubator to maintain body temperature at 37 ± 1 °C and stabilized for 
15-20 minutes and basal values recorded, after were ganglion-blocked 
(0.075 mg/kg/min pentolinium through the experiment). 
 
2.4.4 Vascular reactivity 
Seven animals, per strain and age group, were randomly assigned to 
experimental group and eight to control group. The rats of experimental 
group received iv bolus of cumulative escalating doses of endothelin-1 
(Et-1; 0.03, 0.1, 0.3, 0.5, 1 and 1.5 nmol/kg). The animals assigned to the 
control group of each age and strain, received a similar sequences of 
administrations of physiological saline (1 ml/kg). The parameters 
monitored included: blood pressure (BP), heart rate, cardiac output (CO), 
systemic vascular resistance (SVR) all of which were recorded and 
analyzed continuously via a computerized data acquisition system (IOX 
version 1.7.0, EMKA). The animal were sacrificed by an overdose of 
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Pentobarbital (100 mg/kg i.p.). Hearts, lungs, brain and kidney were 
dried and carefully weighed, then hearts were frozen and stored at -80°C. 
Organs to brain weight ratio were calculated. Organ/brain weight ratios 
was used because the severe obesity makes organ/body weight ratios 
meaningless49. Brain weight reflects lean body mass, is easy to obtain, 
and is reproducible. 
 
2.5 Statistical Analysis 
Results were expressed as mean ± S.E.M. in the form of table and graph. 
Statistical evaluation were performed using Anova on ranks: Kruskal 
Wallis with Dunnet post test, Student t test or ANOVA with the Tuckey’s 
post test for multiple groups as appropriate Graphpad Prism 4 (U.S.A.). 
A value < or = 0.05 was considered statistically significant. 
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3. RESULTS 
3.1 Model of cardiac hypertrophy 
3.1.1 One month coarctation 
Body weight was no statistically significant different between one month 
hypertrophied and sham operated rats (Fig. 1a: 294 ± 16.56 vs 326 ± 8.97 
g; p=0.103 ), as well as lungs and liver weights. On the contrary the ratio 
left ventricular mass/body weight, was statistically significant higher in 
aortic banded rats with respect to sham animals (fig. 1b: 2.68 ± 0.28 vs 
1.87 ± 0.03 mg/g; p= 0.008). At the schedule time, cardiac contractility 
was evaluated on nine of ten clipped animals because one rat died within 
the one-month period, and on eight of ten sham rats because 2 animals 
died during cannulation of the left ventricle. 
Rats abdominal aortic banding did not produce significant changes in 
hemodynamic parameters compared to sham operated: left ventricular 
pressure showed a slight, but statistically non-significant tendency to 
increase (Fig.2a: 175 ± 16.53 vs 154 ± 5.13 mmHg, p=0.532), end-
diastolic pressure (Fig.2b: 12.0 ± 6.38 vs 5.37 ± 5.01 mmHg, p=0.413) 
and heart rate (Fig. 4a: 418  ± 13.20 bpm vs 429 ± 8.37 bpm; p=0.496) 
did not show significant modifications when compared to sham rats. 
The maximal dP/dt showed a slight, but not statistically significant 
decrease versus sham operated rats (Fig. 3a: 4241 ± 587.26 mmHg-sec vs 
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5168 ± 1003.15 mmHg-sec; p=0.425). No significant change was observed 
in –dP/dt (Fig. 3b: -4420 ± 530.49 vs -4780 ± 749.01 mmHg-sec; 
p=0.695). Also, ratio of +dP/dt to left ventricular mass, which can be 
translate as an indirect measure of the contractility efficiency of the heart, 
showed a non-statistically significant to a reduction in hypertrophied rats 
compared to shams (fig. 4b: 5.65 ± 0.73 vs 8.36 ± 1.66 mmHg-sec/mg; 
p=0.140. 
3.1.2 Three-month coarctation 
The mortality of 3-months coarcted rats was higher with respect to those 
of 1 month; in fact, three animals out of ten died within the three-month 
period. No mortal episode occurred in sham operated animals. Body 
weight of three- months coarcted rats did not show statistically 
significant differences from sham animals (Fig. 1a: 326 ± 28.09 vs 417 
±11.55 g; p=0.189). Also lungs and liver weight were not modified by 
aortic coarctation. On the contrary, ratio of left ventricular mass to body 
weight was higher and statistically significant in hypertrophic rats with 
respect to sham animals (Fig. 1b: 2.49 ± 0.36 vs 1.64 ± 0.05 mg/g 
p=0.014). Left ventricular pressure on three-months banded rats showed 
a non statistically significant trend to increase compared to sham 
operated animals (Fig. 2a: 161 ± 10.44 vs 138 ± 5.64 mmHg). Left 
ventricular end-diastolic pressure also showed a non statistically 
significant trend to increase in hypertrophied rats with respect to sham 
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animals (Fig. 2b: 32 ± 8.95 vs 17 ± 5.04). Heart rate did not show 
statistically significant modifications in hypertrophic rats (Fig. 4a: 400 ± 
9.15 vs 394 ± 14.53 bpm; p=0.717) nor did maximal dP/dt (Fig. 3a: 2641 
± 334.36 vs 2818 ± 333.01 mmHg-sec; p=0.722) and - dP/dt (Fig. 3b: -
3126 ± 360.41 vs -2836 ± 307.97 mmHg-sec;p00.551). Measure of the 
contractile efficiency of the heart (ratio of +dP/dt to left ventricular mass) 
was not difference enough between the two groups to consider it 
statistically significant (Fig. 4b: 2.93 ± 0.33 vs 4.23 ± 0.58;p= 0.105). 
Parameter Age, mo SHAM COARTED 
1 154  ± 5.13 175 ± 16.53 LVP. mmHg 3 138 ± 5.64 161 ± 10.44 
    
1 5.37 ± 5.00 12 ± 6.38 LVEDP,mmHg 3 17 ± 5.04 32 ± 8.95 
    
1 429 ± 8.37 418 ± 13.20 HR,mmHg 3 394 ± 9.15 400 ± 14.53 
    
1 5168 ± 2837.33 4241 ± 1761.80 
+dP/dt,mmHg-sec 3 2818 ± 1053.08 2641 ± 884.63 
    
1 -4780 ± 749.01 -4420 ± 530.49 
-dP/dt,mmHg-sec 3 -2836 ± 307.97 -2641 ± 360.41 
    
1 8.36 ± 1.66 5.65 ± 0.73 +dP/dt-LVW, 
mmHg-sec/mg 3 4.23 ± 0.58 2.93 ± 0.33 
Tab 1A.  Basal parameters  of cardiac contractility 
Values are means ± S.E.M. LVP, left ventricular pressure; LVEDP, left ventricular end- 
diastolic pressure; HR, heart rate; +dP/dt, The maximal rate of increase; -dP/dt, 
 the maximal rate of decrease; +dP/dt-LVW, contractile efficiency of the heart .  
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3.2 STZ diabetic rats 
3.2.1 Eleven weeks to induction of diabetes 
3.2.1.1 Basal parameters 
Body weight of 11-weeks STZ rats was markedly reduced (276.6 ± 9.7 
vs 486.4 ± 6.0 g; p< 0.0001) and glycemia was significantly increased 
(492.8 ± 4.1 vs 79.1 ± 2.1 mg/dl; p<0.0001); only systolic blood pressure 
(SBP) showed a slight, but statistically significant reduction in diabetic rats 
with respect to controls before and after ganglion-blocking (Tab. 1B).  
 
 
Tab. 1B Body Weight, basal pressure levels and glycemia  11 weeks to STZ 
inducted diabetes 
Values are mean ± S.E.M. BW, body weight; Gly, glicemia; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; MBP, mean blood pressure. These are value of 
controls and diabetes anesthetized rats after  11 weeks of STZ administering before and 
after ganglion-blocking. * = p<0.05 
 
 
 
 
BW 
g 
Gly 
mg/dl  
SBP 
mmHg 
DBP 
mmHg 
MBP 
mmHg 
 
  
 
 Before  
Controls 486.4 ± 6.0 79.1 ± 2.1  158.3 ± 4.9 123.4 ± 3.9 131.4 ± 5.6 
Diabetes 276.6 ± 9.7٭ 492.8± 4.1٭  144.6± 4.2* 116.5 ± 3.3 125.8 ± 3.6 
   
 
 
 After  
Controls    89.7 ± 3.0 50.1 ± 1.5 63.3 ± 1.9 
Diabetes    75.6± 3.2* 50.3 ± 2.6 58.7 ± 2.7 
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3.2.1.2 Agonist effects 
Phe:  
Diabetic rats showed, after a bolus of Phe, a higher maximal hypertensive 
response with respect to controls (47.8 ± 2.0 vs 60.2 ± 1.7 mmHg; 
p<0.0001) (Fig. 5a). 
Ach: 
Bolus of Ach did not show significant difference for hypotensive 
response between two groups (Fig. 5b). 
Et-1: 
The administration of Et-1 induced a biphasic effects: hypotensive 
following hypertensive response, which were reduced significantly in 
diabetes rats compared with controls. The Dose/ response (D/R) curve of 
hypotensive response for diabetic rats was flat with Emax –22.8 ± 4.2 vs 
-47.7 ± 5.3 mmHg (p< 0.0001; Tab. 2B, Fig. 6a). 
Tab. 2B Pressure effects of Endothelin-1 (Et-1) or big-Endotelin-1 in controls and 
diabetic rats 11 weeks after STZ inducted diabetes. 
Values are mean ± S.E.M. Emax=maximal effect; hypo= hypotension; hyper= 
hypertension; NA= not applicable; Et-1/big-Et-1= potency ratio of two peptides; * = 
p<0.01. 
 
Emax 
∆ mmHg ± sem 
Hypo               Hy; NAper 
ED50 
nmol/kg (95 %) 
Et-1/big 
Et-1 
Ratio 
Et-1 
Controls 
 
Diabetic 
 
-47.7 ± 5.3        102.9 ± 4.2 
 
-22.8 ± 4.2٭       67.5 ± 7.4٭ 
 
0.50 ( 0.44-0.58 ) 
 
0.83 ( 0.63-1.09 )٭ 
 
rbig Et-1 
Controls 
 
Diabetic 
 
NA             103.1 ± 2.8 
 
 NA              72.3± 4.0 ٭ 
 
0.72 ( 0.62-0.84 ) 
 
1.83 ( 1.48- 2.2 ) 
 
0.69 
 
0.45 
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The D/R of hypertensive response for diabetic rats showed a significant 
right shift with a statistically significant increase of ED50: 0.83 (0.63-1.09) 
vs 0.50 (0.44-0.58) nmol/kg and decreasing of the maximal response ( 67.5 
± 7.4 vs 102.9 ± 4.2 mmHg ; p< 0.0001; Tab. 2B, Fig 6b). 
rbig-endothelin: 
The administration of rbig-endothelin produced only hypertensive 
response. Diabetic rats showed a statistically significant reduction of the 
maximal effect exerted by peptide with respect to age-matched rats. The 
D/R curve also was shifted to right, and of ED50, was significantly 
higher in diabetic with respect to controls: 1.83 (1.48-2.2) vs 0.72 (0.62-
0.84) nmol/kg; Tab. 2B, Fig.7a). 
Et-1/rbig Et-1: 
“Potency Ratio”, ratio of ED50 of two peptides, considered as an indirect 
index of ECE activity, was reduced (0.45 vs 0.69) in diabetes rats with 
respect to controls (Tab. 2B). 
Ang II: 
The administration of escalating doses of Angiotensin II induced 
hypertensive dose-dependent effect in all experimental groups.  
In diabetes rats D/R curve  showed a modest right shift with respect to 
controls  without significant modifications of Emax. Moreover, ED50 
was only modestly and non statistically significant reduced in diabetes 
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rats with respect to controls: 33.8 (16-71) and 42.7 (31-59) pmol/kg, 
respectively; Tab. 3B, Fig. 7b). 
 
Tab. 3B Pressure effect of Angiotensin II (AngII) and Angiotensin I (AngI) in 
diabetes and controls rats 
Values are mean ± S.E.M. Emax=maximal effect; AngII/AngI Ratio= potency ratio of 
two peptides; * = p<0.05. 
 
Ang I: 
The administration of escalating doses of Ang I induced dose-dependent 
hypertensive effect in both experimental groups. In diabetes rats the 
curve showed a statistically significant decreasing of the maximal 
pressure effect. ED50 was not significantly different 62.8 (37-107) vs 
108.9 (90-131) pmol/kg  in both groups (Tab.3B, Fig 8). 
Ang II/Ang I: 
“Potency Ratio” (PR) index was 0.54 for diabetic rats and 0.39 for 
normal rats (Tab. 3B). 
 
Emax 
∆ mmHg ± sem 
ED50 
pmol/kg (95 % C.I.) 
Ang II/Ang I 
Ratio 
 
Ang II 
            Controls 
 
            Diabetes 
 
 
109.6± 11 
 
94.3 ± 3.4 
 
 
42.7 ( 31-59 ) 
 
33.8 ( 16.71 ) 
 
 
Ang I 
            Controls 
 
            Diabetes 
 
 
121.7 ± 3.1 
 
89.8 ± 4.6٭ 
 
 
108.9 ( 90-131 ) 
 
62.8 ( 37-107 ) 
 
 
0.39 
 
0.54 
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3.2.2 Eighteen  weeks to induction of diabetes 
3.2.2.1 Basal parameters 
The body weight of diabetic rats was significantly  decreased (292 ± 8 vs 
554 ± 11 g ; p< 0.0001) and glycemia was strongly increased (479.5 ± 
6.6 vs 71.8 ± 1.3 mg/dl; p< 0.0001). Basal pressure levels were 
significantly decreased in diabetes rats.  
There was a decreasing of SBP after ganglion-blocking, while DBP and 
MBP were not statistically different in two groups (tab. 4B). 
 
Tab. 4B Body Weight, basal pressure levels and glycemia 18 weeks to induction 
diabetes 
Values are mean ± S.E.M. BW, body weight; Gly, glicemia; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; MBP, mean blood pressure. These are value of 
controls and diabetes anesthetized rats after  11 weeks of STZ administering before and 
after ganglion-blocking. * = p<0.05 
 
BW 
g 
Gly 
mg/dl  
SBP 
mmHg 
DBP 
mmHg 
MBP 
mmHg 
 
  
 
 Before  
Controls 554 ± 11 71.8 ± 1.3  167.9 ± 2.3 128.8 ± 2.2 141.8 ±2.2 
Diabetic 292 ± 8 479.5 ± 6.6٭  148.0± 4.4٭ 118.0 ± 3.5٭ 128.4± 3.7٭ 
   
 
 
 After  
Controls    95.8 ± 4.6 53.4 ± 2.1 67.5 ± 2.7 
Diabetic    79.6± 2.4٭ 54.7 ± 3.1 63.0 ± 2.8 
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3.2.2.2 Agonist effect 
Phe: 
Diabetes rats showed a significantly reduction of the maximal pressure 
response after bolus of Phe from controls (49.6 ± 2.2 vs 65.7 ± 2.1 
mmHg; p< 0.0001; Tab. 4B, Fig. 9a). 
Ach: 
Bolus of Ach induced a not statistically significant reduction of the maximal 
hypotensive response in diabetic rats with respect to controls (-20.3 ± 1.5 vs -
24. 0 ±  1.1 mmHg; Tab. 4B, Fig. 9b).  
Et-1: 
The administering of Et-1 induced the typical biphasic response: 
hypotension following hypertension, and both components of the 
response were significantly reduced in diabetic  animals with respect to 
controls. The curve of the hypotensive response was significantly shifted 
on the right and Emax reduced in diabetic rats (-19. 9 ± 2.1 vs -60. 1 ± 
8.3mmHg; p < 0.0001; Tab. 5B, Fig. 10a) . 
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Tab. 5B Pressure effect of Endothelin-1 (Et-1) or big-endothelin-1(bigEt-1) in 
controls and diabetes rats 18 weeks to induction diabetes. 
Values are mean ± S.E.M. Emax=maximal effect; hypo= hypotension; hyper= 
hypertension; NA= not applicable; Et-1/big-Et-1= potency ratio of two peptides; * = 
p<0.05. 
 
 
Similarly, the hypertensive phases showed a marked shift to right with a 
significant increased of ED50: 0.75 (0.66-0.85) and 0.46(0.39-0.54) 
nmol/kg respectively, and a reduction of the Emax to the maximal 
experimental doses, (1.5 nmol/kg in controls and 2 nmol/kg in diabetes 
animal) (Tab. 5B, Fig. 10b). Higher doses were lethal. 
rbig-Et-1: 
The administration of rbig Et-1 only produced hypertensive phase in both 
groups. In diabetic animals the maximal response was significantly lower 
than in normal age-matched rats (Tab. 5B, Fig. 12a). Moreover, in 
diabetic animals, D/R curve was shifted to right and ED50 was increased 
significantly: 1.06 (0.84-1.36) nmol/kg vs 0.44 (0.32-0.60) nmol/kg (Tab. 
5B, Fig. 11b). 
 
 
 
Emax 
∆ mmHg ± sem 
 
Hypo               Hyper 
ED50 
nmol/kg (95 % C.I.) 
Et-1/big Et-1 
Ratio 
Et-1 
Controls 
 
Diabetic 
 
-60.1 ± 8.3         87.4 ± 4.2 
 
-19.9 ± 2.1٭       73.2 ± 4.8٭ 
 
0.46 ( 0.39-0.54 ) 
 
0.75 ( 0.66-0.85 )٭ 
 
rbig Et-1 
Controls 
 
Diabetic 
 
NA              99.6 ± 3.7 
 
NA              77.1 ± 4.7٭ 
 
0.44 ( 0.32-0.60 ) 
 
1.06 (0.84-1.36 )٭ 
 
1.08 
 
0.71 
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Et-1/rbig Et-1: 
Finally “Potency Ratio”, index values continued to be lower in diabetic 
compared to age-matched normal rats : 0.71 vs 1.05 (Tab. 5B). 
Ang II: 
The administering of escalating doses of Ang II showed dose-dependent 
pressure effect for both experimental groups. 
Ang II D/R curve was lightly right shifted and Emax reduced, without a 
statistically significant ED50 reduction [49.5 (34-70) vs 51.6 (37-72) 
nmol/kg Tab. 6B, Fig. 12a]. 
Tab. 6B Pressure effect of Angiotensin II (AngII) and Angiotensin I (AngI) in 
diabetes and controls rats 
Values are mean ± S.E.M. Emax=maximal effect; AngII/AngI Ratio= potency ratio of 
two peptides; * = p<0.05. 
 
Ang I: 
Whereas, Ang I administration induced similar pressure response in both 
animal groups without significant variation in Emax or ED50: 99.8 851-
196) vs 97. 9 (69-142) pmol/kg; (fig. 12b). 
 
 
Emax 
∆ mmHg ± sem 
ED50 
pmol/kg (95 % C.I.) 
Ang II/Ang I 
Ratio 
Ang II 
Controls 
 
Diabetic 
 
120.2 ± 7.8 
 
99.6 ± 2.6٭ 
 
51.6 ( 37-72 ) 
 
49.5 ( 34-70 ) 
 
Ang I 
Controls 
 
Diabetic 
 
118.3 ± 4.0 
 
103.0 ± 9.4 
 
 
97.9 ( 69-142 ) 
 
99.8 ( 51-196 ) 
 
 
0.53 
 
0.50 
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Ang II/Ang I: 
Finally,“ Potency Ratio “ (PR) also was similar in both groups (Tab. 6B). 
 
3.3 SHHF as a diabetic cardiomyopathy model 
3.3.1 Six months of age 
3.3.1.1 "Tail Flick" test 
"Tail-Flick" test showed a significant reduction of nociceptive sensibility 
increasing times reaction (Tab. 1C) in SHHF 6.8 (5.0-11.0) sec and SHR 
7.2 (2.8-12.7) sec strains with respect to WKY 2.9 (2.5-3.1) sec or ZDF 
2,8 (2,3-4,2) sec, (p<0.05)  
 
3.3.1.2 Body and organ weights 
SHHF body and organ weights (liver, kidney e left ventricle; Tab. 2C), 
and in ZDF rats kidney and liver weight were statistically significant 
increased respect values found in SHR and WKY rats (p<0.001). 
 
3.3.1.3 Humoral analysis 
Experimental data confirmed metabolic disorders about SHHF and ZDF 
strains. In fact, in fasted animals of both strains has been found the 
typical hematochimical alteration of the Metabolic Syndrome (Tab. 3C) 
ZDF: Tri (889 ± 643 mg/dl); Cho (320±103 mg/dl); Glu (424 ± 
94mg/dl); Ins (2 ± 1 ng/ml); SHHF: Tri (1052 ± 353 mg/dl); Cho (240 ± 
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46 mg/dl); Glu (116 ± 22 mg/dl); Ins (59 ± 17 ng/ml); respect to normal 
levels occurred in others two strains WKY: Tri (83 ± 21 mg/dl); Cho (91 
± 10 mg/d); Glu (106 ± 7 mg/dl) and SHR: Tri (78 ± 16 mg/dl); Cho (64 
± 6 mg/dl); Glu (102 ± 5 mg/dl); Ins (3 ± 1 ng/ml) (p<0.001). 
 
3.3.1.4 Blood pressure, aortic blood flow and skin perfusion flow in 
anesthetized rat before and after ganglion-blocking 
SBP was significantly elevated in SHHF and ZDF rats, before (p<0.04) 
and after (p<0.001) administering of ganglion-blocking agent, compared 
with WKY rats (tab4C-5C) and, significantly (p<0.004) lower compared 
with SHR rats (SBP: 165 ± 6.0 mmHg). In SHR and SHHF rats TPR 
showed values, statistically significantly, higher compared with WKY 
(p=0.01; p= 0.03) and ZDF ( p=0.002;  p=0.02). In SHR rats ABF was 
significantly lower compared to WKY rats (p=0.03). 
PF was significantly lower in SHHF rats with respect to ZDF and SHR 
rats (p<0.001 and  p<0.05, respectively). 
 
3.3.1.5 Vascular reactivity to Et-1 administration 
Due to the high mortality in ZDF group, we excluded it of any 
consideration about Et-1-induced hypertensive responses. 
Et-1 induced hypotension: were not statistically significant differently 
among the remaining all 3 rats strains. Whereas, the maximal hypertensive 
 - 48 - 
response exerted by Et-1 in SHHF (21 ± 19 mmHg) was significant 
reduced with respect to SHR (75 ± 15 mmHg; p=0.05) (Tab. 6C).  
In SHR and SHHF, Et-1-induced TPR increase were minor, although non 
statistically significant, compared with WKY response, in absence of 
ABF modification. Et-1 induced PF modification seemed to be greater in 
SHR and SHHF with respect to WKY. 
 
3.3.2 Ten months of age 
3.3.2.1 "Tail Flick" test 
"Tail-Flick" test  showed a progression nociceptive function impairment 
for SHHF and SHR rats 13.6 (7.8-16.8) (p< 0.05)(Tab. 1C). 
Parameter Age, mo Age, mo 
 6 10 
WKY 2,9(2,5-3,1) 3,0(2,8-3,2) 
   
SHR 7,2(2,8-12,7)* 4,3(3,5-7,5)* 
   
ZDF 2,8(2,3-4,2) 4,3(3,3-5,2) 
   
SHHF 6,8(5,0-11,0)* 13,6(7,8-16,8)* 
Tab 1C. Evaluation of nociceptive activity by " Tail Fick" test. 
Values are median (n=15, animals), in brackets there are ranges 25%-75%. 
The adaptation was 2 minutes for each animals and current intensity 50 mÅ. 
Anova on ranks: Kruskal- Wallis (6 mo) H=21,71; df=3; p<0.0001. 
Dunnett-test;*p<0.05 SHR and SHHF vs WKY. 
Anova on ranks: Kruskal- Wallis (10 mo) H=37,74; df=3; p<0.0001.  
Dunnett-test;* p<0.05 SHR and SHHF vs WKY. 
 
3.3.2.2 Body and organ weights 
At 10-months of age, SHHF still showed cardiac, renal and hepatic 
hypertrophy (Tab. 2C), as demonstrating by remarkable increase of ratio 
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organ weight / brain weight  OW/BrW with respect to all other strains 
(p<0.001). 
Parameter Age, 
mo 
WKY, n=15 SHR, n=15 ZDF, n=15 SHHF, n=15 
6 381 ± 5 343 ± 5 355 ± 14 632 ±  14d BW, g 10 407 ± 5 368 ± 5 324 ±  11 610 ± 45d 
      
6 636 ± 15 718± 11a 676± 18 876 ± 17d LV/BrW, mg 10 690 ± 13 810 ± 25 691 ± 36 967 ± 55d 
      
6 1578 ±37 1766 ±42ab 2866± 106ab 2559 ± 65d KW/BrW, mg 10 1587± 31 1723 ± 33ab 2963 ±231ab 2331 ± 171d 
      
6 6242 ± 111 7061± 12 13675± 853ab 21222 ± 989d 
LW/BrW, mg 10 6790 ± 164 8228 ±305 15789 ± 863ab 15227± 1639d 
Tab 2C. Body weights and organ weights/brain weights 
Values are means ± S.E.M. Both at 6- and 10-months-old n=15 animals WKY, Wistar 
Kyoto; SHR, Spontaneously hypertensive rats; ZDF, Zucker Diabetic Fatty rat; SHHF, 
SHHF/Mcc-fa/fa. 
BW, Body Weight; LV/BrW, left ventricle/Brain weight; KW/BrW, Kidney 
weight/Brain weight; LW/BrW, Liver weight/Brain weight. a Significantly different 
from age-matched WKY; b significantly different from age matched SHR; c 
Significantly different from age-matched ZDF; d Significantly different from age-
matched rats of other strains ( P< 0.001). 
 
3.3.2.3 Humoral analysis 
At ten-months of age SHHF rats confirmed the Metabolic Disorder 
characterized by obesity, high plasmatic level of triglycerides, 
cholesterol, and insulin (p<0.0001), maintaining euglycemic condition 
(Tab. 3C).  
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Parameter Age, mo WKY SHR ZDF SHHF 
6 83.7 ± 21.1 77.9 ± 16.4 889.2 ± 642.6ab 1051.7 ± 353.4d Tri, mg/dL 10 60.3 ± 9.1 66.4 ± 12.7 1503.6 ± 777.9ab 715.7 ± 458.7d 
      
6 90.9 ± 10.2 63.6 ± 5.9 319.5 ± 103.4ab 240.2 ± 45.6d Cho, mg/dL 10 93.9 ± 11.5 64.0 ± 7.6 440.3 ± 142.6ab 218.7 ± 101.9d 
      
6 4.7 ± 1.3 2.7 ± 1.0 1.4 ± 0.4 58.5 ± 17.1d Ins, ng/mL 10 5.1 ± 1.4 3.5 ± 1.1 1.1 ± 0.3 23.5 ± 11.1d 
      
6 106.1 ± 6.5 101.4 ± 5.2 424.7 ± 94.3ab 116.5 ± 21.7c Glu, mg/dL 10 126.3 ± 6.4 119.8 ± 4.6 409.8 ± 122.1ab 113.1 ± 10.9c 
Tab 3C. Metabolic parameters 
Values are means ± S.E.M. Tri, triglyceride; Cho, cholesterol; Ins, insulin; Glu, glucose. 
See table 2C for definition of symbols. 
 
3.3.2.4 Blood pressure, aortic blood flow and skin perfusion flow in 
anesthetized rat before and after ganglion-blocking 
In SHHF strain, SBP was significantly lower compared with SHR rats 
(p=0.01). Instead, in SHR and ZDF rats blood pressure was still higher 
compared with WKY, normotensive control (p=0.005 and p=0.03; 
respectively). TPR and ABF were not statistically significant different 
with respect to all other strains. This suggested that SHHF rats showed  a 
condition of heart failure. Then, in all strains PF did not show statistically 
significant modifications, but SHHF rats showed a slight, but statistically 
significant (p=0.02), reduction with respect to ZDF rats (Tab. 4C-5C). 
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Parameter Age, mo WKY SHR ZDF SHHF 
  
6 mo n=14 
10 mo n=13 
6 mo n=13 
10 mo n=10 
6 mo n=10 
10 mo n=7 
6 mo n=12 
10 mo n=13 
6 114 ± 8 165 ± 6a 136 ± 5ab 137 ±  6ab SBP, mmHg 10 109 ± 3 134 ± 5a 125 ± 7a 107 ± 7b 
      
6 46 ± 10 80 ± 9a 40 ± 5b 90 ± 17ac TPR, AU 10 33 ± 8 74 ± 32 31 ± 6 44 ± 12 
      
6 9 ± 2 5 ± 0.3a 6 ± 1 6 ± 1 ABF, kHz 10 13 ± 1 10 ± 2 9 ± 1 11 ± 1 
      
6 40 ± 3 55 ± 5a 64 ± 6a 33 ± 4bc PF, AU 10 60 ± 6 54 ± 9 85 ± 15 45 ± 7c 
Tab 4C. Hemodynamic basal parameters 
Values are means ± S.E.M. SBP, systolic blood pressure; TPR, tissutal pressure 
resistance; ABF, aortic blood flow; PF, perfusion flow. See table 2C for definition of 
symbols. 
 
Parameter  Age, mo WKY SHR ZDF SHHF 
  
6 mo n=14          
10 mo n=13 
6 mo n=13 
10 mo n=10 
6 mo n=10 
10 mo n=7 
6 mo n=12 
10 mo n=13 
6 61 ± 2 97 ± 5a 78 ± 3a 80 ±  4ab 
SBP, mmHg 10 68 ± 3 77 ± 2a 87 ± 2ab 66 ± 4bc 
      
6 17 ± 2 97 ± 5a 78 ± 3ab 41 ± 10d 
TPR, AU 10 11 ± 1 19 ± 5 19 ± 3a 26 ± 9 
      
6 10 ± 1 5 ± 0.6a 8 ± 1 9 ± 1b 
ABF, kHz 10 15 ± 1 13 ± 2 4 ± 1 12 ± 1 
      
6 42 ± 6 97 ± 5a 78 ± 3ab 39 ± 5bc PF, AU 
  10 62 ± 10 47 ± 7 88 ± 17b 72 ± 26 
Tab 5C. Hemodynamic parameters after  ganglion-blocking agent infusion  
(Pentolinium 0.075 mg/kg) 
Values are means ± S.E.M. SBP, systolic blood pressure; TPR, tissutal pressure resistance;  
 ABF, aortic blood flow; PF, perfusion flow. See table 2C for definition of symbols.  
 
3.3.2.5 Vascular reactivity  of Et-1 administration 
At 10-months of age, the administration of Et-1 induced the maximal 
SBP increase in SHR with respect to WKY and SHHF. The variations 
 - 52 - 
induced by Et-1 on all other monitored parameters were non statistically 
significantly, although in SHR the TPR were tendentially higher than in 
SHHF and WKY; ABF less reduced in SHR with respect to SHHF and 
WKY and PF lower SHHF compared with SHR and WKY rats (Tab. 6C). 
Parameter Age, mo WKY SHR SHHF 
  
6 mo n=6 
10 mo n=7 
6 mo n=7 
10 mo n=5 
6 mo n=5 
10 mo n=6 
6 48 ± 24 75 ± 15 21 ± 19b 
∆SBP, mmHg 10 57 ± 18 88 ± 8 59 ± 10 
     
6 39 ± 21 10 ± 46 16 ± 30 
∆TPR, mmHg 10 38 ± 11 56 ± 23 28 ± 25 
     
6 -0.3 ± 2 0.5 ± 1 -1.8 ± 2 
∆ABF, kHz 10 -5.7 ± 1.7 -3.1 ± 1.6 -4.3 ± 2.3 
     
6 34 ± 16 77 ± 35 61 ± 56 ∆PF, mmHg 
 10 81 ± 46 54 ± 13 38 ± 38 
Tab 6C.The maximal responses after bolus Et-1(1.5 nmol/kg) in anesthetized and 
ganglion-blocked animals. 
Values are means ± S.E.M. SBP, systolic blood pressure; TPR, tissutal pressure resistance; 
ABF, aortic blood flow; PF, perfusion flow. See table 2C for definition of symbols. 
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4. DISCUSSION 
It is well established that diabetic cardiomyopathy contributes to the 
heart failure and results in the high mortality rate observed in diabetic 
patients independent  of coronary heart disease.  
The purpose of the present study was to obtain an adequate model to 
investigate physiopatological modifications in diabetic cardiomyopathy. 
Initially we decided to associate the diabetes with cardiac hypertrophy  
model, that it is validated in our laboratories. To choose the level of 
cardiac hypertrophy before the induction of diabetes, we studied cardiac 
hypertrophy progression 1- and 3-months after abdominal aortic banding. 
The results obtained suggest that the cardiac hypertrophy occurring from 
pressure overload due to abdominal aortic banding in both 1- and 3-
months coarcted rats, is hemodynamically compensated; in fact, the 
statistically significant increase of left ventricular mass occurs without 
compromising hemodynamic parameters such as the contractile and 
relaxation efficiency of the heart. Thus, for our purpose, we consider the 
hypertrophy induced by 1-month of aortic coarctation sufficient as 
background hypertrophic cardiomyopathy. Then, we induced diabetes in 
1-month  aortic coarctation rats. 
Subsequently, to choose the duration of diabetes that produces 
cardiovascular modification, we valuated the vascular reactivity in STZ-
induced diabetic rats after 11- and 18-weeks. STZ-induced diabetic rats 
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showed a remarkable homogeneity in body weight a glycemic plasma 
level. These findings strongly suggest that physiopathological alteration 
observed are strictly correlated to the diabetic condition. In diabetic 
animals basal systemic pressure occurs significantly  lower compared 
with controls at 18-weeks after diabetes induction, while at 11-weeks 
after diabetes induction diabetic animals only shows a significantly 
reduction of the systemic blood pressure. The ganglion-blocking agent 
antagonized sympathetic tone in the diabetic animals to compensate for 
hypotension tendency. In fact, in diabetic animals there is a reduced 
responsiveness to Phe, α1-agonist; a chronic increased of basal 
sympathetic tone could take to a “ down regulation” of the α-receptor  
with consequent reduction of the response to the exogenous stimulus. 
The experimental dates show an evident reduction of efficiency and  
potency of Et-1 to 11-week, reduction of the velocity of conversion 
rbig→Et-1 and reduction of the ratio Et-1/big Et-1 in diabetes rats 
compared with age-matched both 11-week and 18-week.  In diabetic rats 
there is a great reduction of hypotensive phase with a normal response to 
Ach. This result suggests that population of Et-s receptor (ET-B) could 
be altered. The reduction of the maximal hypertensive response of Et-1 
suggests an “alteration“ also in the population of receptor of Et-1 of the 
vascular smooth muscle cells (VSMC). The ratio of potency of Et-1 
among two groups (C/D ratio) is 0.60 at 11 weeks and 0.61 at 18 weeks. 
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This result suggest a reduction of the number of receptor for Et-1. ED50 
Et-1/bigEt-1 showed at 11- and 18-weeks in diabetes rats (ratio = 0.45 
and 0.71) with compared to controls with PR 0.69 and 1.08 
(respectively), confirming the of hypothesis “alteration “ of ECE activity 
during diabetic pathology. The results about renin-angiotensin system 
suggest  that in diabetes rats Ang II shows a reasonable reduction of 
efficiency and potency with respect to controls. The same result we have 
with pro-peptide,  Ang I, that, after conversion in  Ang II  with ACE, 
induce pressure response. The ratio of potency  Ang II/Ang I is not 
different in both groups at 11-and 18-weeks. Then, in experimental 
diabetes renin-angiotensin system shows an evident alteration of the 
vasoconstrictor function of the active peptide while the conversion 
AngI→AngII with ACE do not change. Then, in the similar pathologic 
conditions, renin-angiotensin and endothelin system react  in different 
way. There is a selective alteration in vasal function during the 
development of diabetic pathology. The correlation between 
experimental dates and the physiopathology of the typical vascular 
complications of the diabetic pathology is not clear.  
Afterwards, diabetes was induced to hypertophic rats, but high mortality 
showed under that conditions induced us to abandon this model, at that 
point was necessary to use a different model to study evolution of 
diabetic cardiomyopathy. The commercial availability of SHHF rat 
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induced as to characterize it. Thus a novel comprehensive evaluation of 
the functional and humoral expression of physiopathology of this rat 
strain was conducted in the obese male SHHF rat model compared with 
age-matched controls (WKY), hypertensive (SHR) and diabetic (ZDF) 
rats at 6- and 10-months of age. The results obtained showed that SHHF 
strain present the characteristic of Metabolic Syndrome: 
hypertrigliceridemia, hypercholesterolemia, hyperinsulinemia, in 
euglycemic condition with respect to all other strains both at 6- and at 10-
months of age. Then, SHHF rats had significantly elevated body weight, 
elevated LvW/BrW with respect to WKY and SHR strains. This result 
confirmed that SHHF rats were characterized by metabolic syndrome and 
cardiac hypertrophy. Compared with age-matched WKY rats, resting 
blood pressure was elevated in all SHHF rats; compared with 10-month-
old, blood pressure BF and PF were significantly decreased but not TPR, 
index of  probably cardiac dysfunction. The results, obtained by tail flick 
test, showed that SHHF rats had a significantly elevated time of reaction 
especially at 10-month-old, index of progressive of diabetic neuropathy, 
another diabetic complication. Furthermore, SHHF strains showed a 
increased vascular reactivity to vasoconstrictor agent like Et-1 during 
different age (6- and 10- months-old). In conclusion, these result identify 
SHHF Mcc-fa/fa rat as a congenital model to better helpful to investigate 
the physiopathology modifications that lead to diabetic cardiomiopathy. 
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